Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
4,440,602
-
Number of holders
-
5
-
Total 13F shares, excl. options
-
218,370
-
Shares change
-
+147,593
-
Total reported value, excl. options
-
$423,638
-
Value change
-
+$328,879
-
Number of buys
-
5
-
Number of sells
-
-4
-
Price
-
$1.94
Significant Holders of Virax Biolabs Group Ltd - Ordinary Shares (VRAX) as of Q3 2024
9 filings reported holding VRAX - Virax Biolabs Group Ltd - Ordinary Shares as of Q3 2024.
Virax Biolabs Group Ltd - Ordinary Shares (VRAX) has 5 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 218,370 shares
of 4,440,602 outstanding shares and own 4.9% of the company stock.
Largest 9 shareholders include RENAISSANCE TECHNOLOGIES LLC (145,400 shares), Squarepoint Ops LLC (40,620 shares), UBS Group AG (20,530 shares), JANE STREET GROUP, LLC (11,635 shares), Headlands Technologies LLC (185 shares), Virtu Financial LLC (0 shares), HRT FINANCIAL LP (0 shares), WELLS FARGO & COMPANY/MN (0 shares), and Qube Research & Technologies Ltd (0 shares).
This table shows the top 5 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.